UA112522C2 - Спосіб терапії злоякісної пухлини - Google Patents
Спосіб терапії злоякісної пухлиниInfo
- Publication number
- UA112522C2 UA112522C2 UAA201215130A UAA201215130A UA112522C2 UA 112522 C2 UA112522 C2 UA 112522C2 UA A201215130 A UAA201215130 A UA A201215130A UA A201215130 A UAA201215130 A UA A201215130A UA 112522 C2 UA112522 C2 UA 112522C2
- Authority
- UA
- Ukraine
- Prior art keywords
- therapy
- increase
- nuclear localization
- protein
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
У цьому винаході описаний спосіб лікування злоякісної пухлини за допомогою збільшення ядерної локалізації білка COMMD1, яке асоційоване зі зниженням або блокуванням проліферації клітин злоякісної пухлини. Винахід також стосується застосування засобів, які збільшують ядерну локалізацію білка COMMD1, у виготовленні лікарського засобу для терапії злоякісної пухлини. Ці засоби можуть являти собою пептиди або білки, серед інших сполук. Винахід також стосується оптимізації пептиду, що походить з послідовності HARIKPTFRRLKWKKYKGKFW, для збільшення ядерної локалізації білка COMMD і, таким чином, для збільшення протипухлинного ефекту цього пептиду.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2010000113A CU23897B1 (es) | 2010-05-31 | 2010-05-31 | Péptido para la terapia del cáncer |
PCT/CU2011/000003 WO2011150897A2 (es) | 2010-05-31 | 2011-05-31 | Método para la terapia del cáncer |
Publications (1)
Publication Number | Publication Date |
---|---|
UA112522C2 true UA112522C2 (uk) | 2016-09-26 |
Family
ID=45067129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201215130A UA112522C2 (uk) | 2010-05-31 | 2011-05-31 | Спосіб терапії злоякісної пухлини |
Country Status (16)
Country | Link |
---|---|
US (2) | US8729226B2 (uk) |
EP (1) | EP2578227B1 (uk) |
JP (1) | JP5827322B2 (uk) |
KR (1) | KR101847170B1 (uk) |
CN (1) | CN102917725B (uk) |
AR (1) | AR081259A1 (uk) |
AU (1) | AU2011260745B2 (uk) |
BR (1) | BR112012030668B1 (uk) |
CA (1) | CA2799066C (uk) |
CU (1) | CU23897B1 (uk) |
DK (1) | DK2578227T3 (uk) |
MX (1) | MX2012013923A (uk) |
RU (1) | RU2577993C2 (uk) |
UA (1) | UA112522C2 (uk) |
WO (1) | WO2011150897A2 (uk) |
ZA (1) | ZA201208905B (uk) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2105567C1 (ru) * | 1995-12-01 | 1998-02-27 | Сергей Юрьевич Родионов | Способ лечения злокачественных опухолей |
CU23582A1 (es) * | 2006-02-24 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Péptidos con capacidad anti-tumoral e inmunomoduladora |
CU23674A1 (es) | 2007-07-31 | 2011-05-27 | Ct Ingenieria Genetica Biotech | Péptidos penetradores a células fusionados a una biomolécula con acción terapéutica |
-
2010
- 2010-05-31 CU CU2010000113A patent/CU23897B1/es active IP Right Grant
-
2011
- 2011-05-27 AR ARP110101831A patent/AR081259A1/es active IP Right Grant
- 2011-05-31 CA CA2799066A patent/CA2799066C/en active Active
- 2011-05-31 RU RU2012157289/10A patent/RU2577993C2/ru active
- 2011-05-31 JP JP2013512751A patent/JP5827322B2/ja active Active
- 2011-05-31 UA UAA201215130A patent/UA112522C2/uk unknown
- 2011-05-31 MX MX2012013923A patent/MX2012013923A/es active IP Right Grant
- 2011-05-31 WO PCT/CU2011/000003 patent/WO2011150897A2/es active Application Filing
- 2011-05-31 US US13/700,286 patent/US8729226B2/en active Active
- 2011-05-31 CN CN201180026853.7A patent/CN102917725B/zh active Active
- 2011-05-31 DK DK11728172.5T patent/DK2578227T3/en active
- 2011-05-31 KR KR1020127033777A patent/KR101847170B1/ko active IP Right Grant
- 2011-05-31 AU AU2011260745A patent/AU2011260745B2/en active Active
- 2011-05-31 EP EP11728172.5A patent/EP2578227B1/en active Active
- 2011-05-31 BR BR112012030668-5A patent/BR112012030668B1/pt active IP Right Grant
-
2012
- 2012-11-26 ZA ZA2012/08905A patent/ZA201208905B/en unknown
-
2013
- 2013-11-08 US US14/075,276 patent/US9145554B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8729226B2 (en) | 2014-05-20 |
EP2578227B1 (en) | 2016-12-28 |
WO2011150897A3 (es) | 2012-03-15 |
ZA201208905B (en) | 2013-07-31 |
US20140206621A1 (en) | 2014-07-24 |
AU2011260745A1 (en) | 2012-12-06 |
EP2578227A2 (en) | 2013-04-10 |
MX2012013923A (es) | 2013-01-24 |
CN102917725A (zh) | 2013-02-06 |
CN102917725B (zh) | 2014-09-17 |
RU2577993C2 (ru) | 2016-03-20 |
AU2011260745B2 (en) | 2014-08-07 |
BR112012030668A2 (pt) | 2020-08-25 |
US20130224313A1 (en) | 2013-08-29 |
CA2799066A1 (en) | 2011-12-08 |
CA2799066C (en) | 2019-07-23 |
US9145554B2 (en) | 2015-09-29 |
CU23897B1 (es) | 2013-05-31 |
DK2578227T3 (en) | 2017-03-27 |
RU2012157289A (ru) | 2014-07-20 |
JP2013530162A (ja) | 2013-07-25 |
AR081259A1 (es) | 2012-07-18 |
KR101847170B1 (ko) | 2018-05-28 |
JP5827322B2 (ja) | 2015-12-02 |
BR112012030668B1 (pt) | 2022-03-29 |
WO2011150897A2 (es) | 2011-12-08 |
KR20130089167A (ko) | 2013-08-09 |
CU20100113A7 (es) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501264A1 (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
ZA201906269B (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
AU2018253546A1 (en) | Aromatic-cationic peptides and methods for using same | |
IN2015KN00350A (uk) | ||
MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
UA107706C2 (uk) | Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань | |
BR112012024382A2 (pt) | agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças | |
EA201201186A1 (ru) | ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ | |
IN2014KN01715A (uk) | ||
MX2015002371A (es) | Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos. | |
MY167232A (en) | Polypeptides binding to human complement c5 | |
MX2015005252A (es) | Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1. | |
EA201291195A1 (ru) | Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1 | |
EA201390506A1 (ru) | Полипептиды, которые связывают компонент с5 комплемента человека | |
MX338981B (es) | Proteina de fusion robo1-fc y sus uso en el tratamiento de tumores. | |
NZ715177A (en) | Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
BR112018075660A2 (pt) | métodos de tratamento de câncer de pâncreas | |
SG191060A1 (en) | Robo1-fc fusion protein for use in the treatment of hepatocarcinoma | |
BR112016023011A2 (pt) | tratamento de câncer gástrico | |
EA201491352A1 (ru) | Способ лечения рака груди | |
BR102012006063A8 (pt) | Inibidor de met para uso no tratamento de um paciente sofrendo de um tumor, e, sequência de nucleotídeo | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
UA112522C2 (uk) | Спосіб терапії злоякісної пухлини | |
EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина |